However, autoantibodies are of limited use to predict the onset of specific complications (6–8); other biomarkers, such as uric acid and NT-ProBNP are instrumental to assess the risk of having PAH (9), KL-6 may predict the progression of SSc-ILD (10), while the combination of serum NT-ProBNP and troponins may be evocative of myocardial involvement (11, 12). This evidence concerns the gene MUC1 and interstitial lung disease.